Compare Stocks

→ Elon’s New Device is About to Shock the World (From InvestorPlace) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTIC CTI BioPharma	$9.09	$9.06	$4.01 ▼ $9.10	$1.20B	0.83	4.50 million shs	N/A
KNTE Kinnate Biopharma	$2.65 -0.4%	$2.61	$1.04 ▼ $7.18	$125.13M	1.38	418,678 shs	2.81 million shs
TSVT 2seventy bio	$4.76 -3.4%	$4.95	$1.53 ▼ $12.69	$244.66M	1.87	1.06 million shs	598,347 shs
VRNA Verona Pharma	$15.69 -0.4%	$16.21	$11.83 ▼ $23.81	$1.24B	0.43	441,820 shs	507,486 shs

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTIC CTI BioPharma	0.00%	0.00%	0.00%	0.00%	+75.82%
KNTE Kinnate Biopharma	0.00%	0.00%	0.00%	+9.96%	-8.93%
TSVT 2seventy bio	-3.45%	+11.87%	-4.42%	-9.33%	-52.64%
VRNA Verona Pharma	-0.38%	+1.42%	-3.33%	-14.31%	-25.96%

Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (Ad)

The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty.

See why the elites are pouring billions into gold.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CTIC CTI BioPharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
KNTE Kinnate Biopharma	2.6292 of 5 stars	3.0	0.0	0.0	4.7	0.0	3.3	1.3
TSVT 2seventy bio	2.7213 of 5 stars	3.2	2.0	0.0	0.0	2.4	3.3	1.3
VRNA Verona Pharma	2.1189 of 5 stars	3.5	2.0	0.0	0.0	1.8	2.5	0.6

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CTIC CTI BioPharma	2.00	Hold	N/A	N/A
KNTE Kinnate Biopharma	2.00	Hold	$8.15	207.45% Upside
TSVT 2seventy bio	2.38	Hold	$13.17	176.61% Upside
VRNA Verona Pharma	3.00	Buy	$33.60	114.15% Upside

Current Analyst Ratings

Latest CTIC, VRNA, KNTE, and TSVT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/16/2024	VRNA Verona Pharma	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$31.00 ➝ $36.00
4/8/2024	TSVT 2seventy bio	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$9.00 ➝ $12.00
3/18/2024	TSVT 2seventy bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$5.00
3/4/2024	VRNA Verona Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00
3/1/2024	VRNA Verona Pharma	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$33.00
2/26/2024	KNTE Kinnate Biopharma	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$2.59
2/16/2024	KNTE Kinnate Biopharma	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform

(Data available from 5/4/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CTIC CTI BioPharma	$53M	22.62	N/A	N/A	($0.14) per share	-64.93
KNTE Kinnate Biopharma	N/A	N/A	N/A	N/A	$5.06 per share	N/A
TSVT 2seventy bio	$100.39M	2.44	N/A	N/A	$5.04 per share	0.94
VRNA Verona Pharma	$460K	2,694.25	N/A	N/A	$3.10 per share	5.06

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CTIC CTI BioPharma	-$92.99M	-$0.58	N/A	26.74	N/A	-91.38%	N/A	-55.82%	N/A
KNTE Kinnate Biopharma	-$116.27M	-$2.78	N/A	N/A	N/A	N/A	-62.31%	-54.72%	5/9/2024 (Estimated)
TSVT 2seventy bio	-$217.57M	-$4.42	N/A	68.00	N/A	-216.73%	-59.19%	-29.67%	5/8/2024 (Confirmed)
VRNA Verona Pharma	-$54.37M	-$0.69	N/A	N/A	N/A	N/A	-20.47%	-17.72%	5/9/2024 (Confirmed)

Latest CTIC, VRNA, KNTE, and TSVT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/9/2024	N/A	VRNA Verona Pharma	-$0.24	N/A	+$0.24	N/A	N/A	N/A
5/8/2024	N/A	TSVT 2seventy bio	-$0.72	N/A	+$0.72	N/A	N/A	N/A
3/5/2024	12/31/2023	TSVT 2seventy bio	-$1.22	-$1.11	+$0.11	-$1.11	$13.91 million	$10.68 million
2/29/2024	Q4 2023	VRNA Verona Pharma	-$0.23	-$0.16	+$0.07	-$0.16	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CTIC CTI BioPharma	N/A	N/A	N/A	N/A	N/A
KNTE Kinnate Biopharma	N/A	N/A	N/A	N/A	N/A
TSVT 2seventy bio	N/A	N/A	N/A	N/A	N/A
VRNA Verona Pharma	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CTIC CTI BioPharma	N/A	1.27	1.26
KNTE Kinnate Biopharma	N/A	10.80	10.80
TSVT 2seventy bio	N/A	3.98	3.98
VRNA Verona Pharma	0.20	33.33	33.33

Ownership

Institutional Ownership

Company	Institutional Ownership
CTIC CTI BioPharma	91.45%
KNTE Kinnate Biopharma	80.89%
TSVT 2seventy bio	93.90%
VRNA Verona Pharma	85.88%

Insider Ownership

Company	Insider Ownership
CTIC CTI BioPharma	7.61%
KNTE Kinnate Biopharma	41.70%
TSVT 2seventy bio	2.60%
VRNA Verona Pharma	4.80%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
CTIC CTI BioPharma	127	131.88 million	121.84 million	Optionable
KNTE Kinnate Biopharma	84	47.22 million	27.53 million	Optionable
TSVT 2seventy bio	274	51.40 million	50.07 million	Optionable
VRNA Verona Pharma	79	78.99 million	76.94 million	Optionable

CTIC, VRNA, KNTE, and TSVT Headlines

Source	Headline
	Kathleen A. Rickard Sells 36,248 Shares of Verona Pharma plc (NASDAQ:VRNA) Stock insidertrades.com - May 4 at 8:12 AM
	Verona Pharma plc (NASDAQ:VRNA) Insider Kathleen A. Rickard Sells 36,248 Shares marketbeat.com - May 3 at 10:24 PM
	Verona Pharma (VRNA) Set to Announce Quarterly Earnings on Thursday americanbankingnews.com - May 2 at 3:34 AM
	Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at ATS 2024 globenewswire.com - May 2 at 2:00 AM
	Verona Pharma plc (NASDAQ:VRNA) is Vivo Capital LLC's 6th Largest Position marketbeat.com - April 27 at 9:40 PM
	Jennison Associates LLC Acquires 142,819 Shares of Verona Pharma plc (NASDAQ:VRNA) marketbeat.com - April 25 at 7:26 AM
	Verona Pharma shares target raised on COPD launch outlook investing.com - April 25 at 3:40 AM
	Verona Pharma to Report First Quarter 2024 Financial Results and Provide Corporate Update globenewswire.com - April 25 at 2:00 AM
	Verona Pharma (NASDAQ:VRNA) Stock Price Up 3.7% on Analyst Upgrade marketbeat.com - April 16 at 10:36 AM
	Verona Pharma (NASDAQ:VRNA) PT Raised to $36.00 at Piper Sandler marketbeat.com - April 16 at 8:33 AM
	Verona Pharma (NASDAQ:VRNA) Shares Up 4.9% marketbeat.com - April 4 at 3:08 PM
	VRNA Apr 2024 17.500 call finance.yahoo.com - March 16 at 8:32 AM
	VRNA Apr 2024 15.000 call finance.yahoo.com - March 16 at 3:31 AM
	Andrew Fisher Joins Verona Pharma as General Counsel globenewswire.com - March 4 at 2:00 AM
	Buy Rating Affirmed: Verona Pharma’s Promising Future with Ensifentrine and Expanding R&D Pipeline markets.businessinsider.com - March 1 at 1:10 PM
	Verona Pharma plc (NASDAQ:VRNA) Q4 2023 Earnings Call Transcript finance.yahoo.com - March 1 at 1:10 PM
	3 Healthcare Stocks That Have Outperformed Nvidia Since 2022 fool.com - March 1 at 8:45 AM
	Verona Pharma plc 2023 Q4 - Results - Earnings Call Presentation seekingalpha.com - February 29 at 11:18 AM
	Verona Pharma plc: Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update finanznachrichten.de - February 29 at 10:48 AM
	Verona Pharma PLC Reports Fourth Quarter and Full Year 2023 Financial Results finance.yahoo.com - February 29 at 10:48 AM
	Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update globenewswire.com - February 29 at 2:00 AM
	Verona Pharma earnings preview: what to expect markets.businessinsider.com - February 28 at 1:35 PM
	When Will Verona Pharma plc (NASDAQ:VRNA) Turn A Profit? finance.yahoo.com - February 25 at 12:52 PM
	Verona Pharma PLC ADR wsj.com - February 25 at 7:52 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

CTI BioPharma

NASDAQ:CTIC

CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an an oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. CTI BioPharma Corp. has license and collaboration agreement with Teva Pharmaceutical Industries Ltd. and S*BIO Pte Ltd. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.

Kinnate Biopharma

NASDAQ:KNTE

Kinnate Biopharma Inc., a clinical-stage oncology company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.

2seventy bio

NASDAQ:TSVT

2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.

Verona Pharma

NASDAQ:VRNA

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial